- Home
- CNTB vs LUCD Comparison
CNTB vs LUCD Comparison
Compare CNTB & LUCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTB
- LUCD
- Stock Information
- Founded
- CNTB 2012
- LUCD 2018
- Country
- CNTB United States
- LUCD United States
- Employees
- CNTB N/A
- LUCD N/A
- Industry
- CNTB Biotechnology: Pharmaceutical Preparations
- LUCD Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- CNTB Health Care
- LUCD Health Care
- Exchange
- CNTB Nasdaq
- LUCD Nasdaq
- Market Cap
- CNTB 94.2M
- LUCD 108.0M
- IPO Year
- CNTB 2021
- LUCD 2021
- Fundamental
- Price
- CNTB $1.59
- LUCD $1.27
- Analyst Decision
- CNTB Strong Buy
- LUCD Strong Buy
- Analyst Count
- CNTB 2
- LUCD 5
- Target Price
- CNTB $7.50
- LUCD $3.70
- AVG Volume (30 Days)
- CNTB 79.5K
- LUCD 1.3M
- Earning Date
- CNTB 11-30-2025
- LUCD 11-12-2025
- Dividend Yield
- CNTB N/A
- LUCD N/A
- EPS Growth
- CNTB N/A
- LUCD N/A
- EPS
- CNTB N/A
- LUCD N/A
- Revenue
- CNTB $1,965,000.00
- LUCD $4,360,000.00
- Revenue This Year
- CNTB N/A
- LUCD $13.90
- Revenue Next Year
- CNTB $453,067.90
- LUCD $154.24
- P/E Ratio
- CNTB N/A
- LUCD N/A
- Revenue Growth
- CNTB N/A
- LUCD 14.74
- 52 Week Low
- CNTB $1.23
- LUCD $0.75
- 52 Week High
- CNTB $2.20
- LUCD $1.80
- Technical
- Relative Strength Index (RSI)
- CNTB 45.14
- LUCD 60.66
- Support Level
- CNTB $1.50
- LUCD $1.24
- Resistance Level
- CNTB $1.72
- LUCD $1.27
- Average True Range (ATR)
- CNTB 0.13
- LUCD 0.06
- MACD
- CNTB -0.02
- LUCD 0.01
- Stochastic Oscillator
- CNTB 18.00
- LUCD 86.47
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.
About LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.